Browsing by Author "Stoian, Anca Pantea"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDLPublication . Vekic, Jelena; Zeljkovic, Aleksandra; Stefanovic, Aleksandra; Bogavac-Stanojevic, Natasa; Ilias, Ioannis; Silva-Nunes, José; Stoian, Anca Pantea; Janez, Andrej; Rizzo, ManfrediCompelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier, and longer intervention to reduce LDL-C levels, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
- The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanismPublication . Banerjee, Yajnavalka; Stoian, Anca Pantea; Silva-Nunes, José; Sonmez, Alper; Rizvi, Ali A.; Janez, Andrej; Rizzo, ManfrediIntroduction: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose-reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose-lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic, and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. Areas covered: In the present article we propose a hypothetical molecular mechanism by which GLP1-RAs may interact with SARS-CoV-2 activity. Expert opinion: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature.